Personalis Inc., an advanced genomics provider for precision oncology, will continue its collaboration with AstraZeneca Pharmaceuticals to explore ultra-sensitive molecular residual disease (MRD) measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development.   The two companies are collaborating to evaluate the sensitivity and specificity potential of whole-genome-informed circulating tumor DNA (ctDNA) testing, while simultaneously det...